Financials in USD. Standardized financial statements.
A compact view of how Celyad Oncology S.A. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $186,000 | $102,000 | $0 | $0 | $5,000 | $6,000 | $3.12M | $3.54M | $10.01M | $3,000 |
| Revenue Growth? | +82.4% | 0.0% | 0.0% | -100.0% | -16.7% | -99.8% | -12.0% | -64.6% | +333633.3% | 0.0% |
| Cost of Revenue? | $12,000 | $69,000 | $1.44M | $1.52M | $0 | $0 | $0 | $515,000 | $1.54M | $2,000 |
| Gross Profit? | $174,000 | $33,000 | -$1.44M | -$1.52M | $5,000 | $6,000 | $3.12M | $3.02M | $8.47M | $1,000 |
| Gross Margin? | +93.5% | +32.4% | 0.0% | 0.0% | +100.0% | +100.0% | +100.0% | +85.5% | +84.6% | +33.3% |
| Operating Expenses? | $6.03M | $8.49M | $20.26M | $26.91M | $26.24M | $29.38M | $41.28M | $55.90M | $34.08M | $29.68M |
| Operating Income? | -$5.86M | -$8.46M | -$40.86M | -$26.39M | -$16.99M | -$28.88M | -$38.17M | -$52.88M | -$25.61M | -$29.67M |
| EBITDA? | -$5.69M | -$7.76M | -$39.70M | -$25.41M | -$14.94M | -$26.51M | -$36.25M | -$55.70M | -$21.99M | -$28.07M |
| Income Before Tax | -$5.82M | -$8.64M | -$40.87M | -$26.50M | -$17.20M | -$28.64M | -$37.43M | -$56.40M | -$23.61M | -$29.11M |
| Income Tax Expense | $0 | -$191,000 | $65,000 | $10,000 | $0 | -$8,000 | $0 | -$1,000 | -$6,000 | -$55,000 |
| Net Income? | -$5.82M | -$8.45M | -$40.94M | -$26.51M | -$17.50M | -$28.63M | -$37.43M | -$56.40M | -$23.61M | -$29.11M |
| EPS? | $-0.14 | $-0.33 | $-1.81 | $-1.70 | $-1.26 | $-2.29 | $-3.26 | $-5.86 | $-2.53 | $-3.43 |
| Diluted EPS? | $-0.14 | $-0.33 | $-1.81 | $-1.70 | $-1.26 | $-2.29 | $-3.26 | $-5.86 | $-2.53 | $-3.43 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality